^
Association details:
| Biomarker: | ROS1 positive |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lorlatinib Combinations in Lung Cancer
Excerpt:
...- Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (Stage IV, AJCC v7.0) that carries an ALK or ROS1 rearrangement (ROS1-positive patients will only be allowed in dose escalation) as determined using a local diagnostic test or a commercial test or by the Food and Drug Administration (FDA)-approved FISH test, using Vysis® ALK Break apart FISH Probe, or the Ventana® immunohistochemistry (IHC) test....
Trial ID:
Source:
Title:
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Excerpt:
...All patients (ALK positive and ROS1 positive) must have archival tissue sample available and collected prior to enrollment....
Trial ID:
More C2 evidence
Source:
Title:
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Excerpt:
...- For ROS1 positive patients: failure to prior treatment with at least crizotinib...
Trial ID:
Less C2 evidence
Source:
Title:
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Published date:
11/17/2020
Excerpt:
There were 41 patients in the database who received Lorlatinib...Three patients were ROS1 positive...Seventy three percent showed clinical response to therapy with median PFS and OS of 16 months (95% CI 14.0-18.2) and 23 months (95% CI 14.6-31.3) respectively.
